您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > MKC-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MKC-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MKC-1图片
规格:98%
分子量:400.39
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
MKC-1 (Ro-31-7453) 是一种口服有效的细胞周期抑制剂,具有广泛的抗肿瘤活性。MKC-1 抑制 Akt/mTOR 通路。通过结合一系列不同的细胞蛋白,包括微管蛋白 (tubulin) 和导入蛋白 β (importin β) 家族成员,MKC-1 阻止细胞有丝分裂并诱导细胞凋亡 (apoptosis)。
货号:ajcx39000
CAS:125313-92-0
分子式:C22H16N4O4
分子量:400.39
溶解度:N/A
纯度:98%
存储:Store at -20°C
库存:现货

Background:

MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family[1][2][3].

MKC-1 (200 mg/kg, orally, daily) significantly increased the median survival time (MST) of mice bearing Caki-1 renal cell xenograft tumors[3].

[1]. Wang M, et al. The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent. Nucl Med Biol. 2010 Oct;37(7):763-75.
[2]. Faris JE, et al. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug;30(4):1614-20.
[3]. Burke P, et al. MKC-1 significantly increases survival of mice bearing renal cell carcinoma Caki-1 xenograft tumors through inhibition of the Akt/mTOR pathway[J]. Molecular Cancer Therapeutics, 2007(12):3524S-3525S.